Page last updated: 2024-11-12

deoxycortone pivalate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11876263
CHEMBL ID1200592
CHEBI ID50782
SCHEMBL ID120007
MeSH IDM0071704

Synonyms (76)

Synonym
deoxycorticosterone trimethylacetate
neodin-depositum
deoxycortone trimethylacetate
percorten pivalate
808-48-0
deoxycorticosterone pivalate
desoxycorticosterone trimethylacetate
cortexone m
11-deoxycorticosterone, pivalate
percorten m
desoxycorticosterone pivalate
dtma
nsc-95278
corticosterone, deoxy-, pivalate
16665t4a2x ,
unii-16665t4a2x
4-08-00-02196 (beilstein handbook reference)
desoxycorticosterone pivalate [usp]
percorten v
percorten (tn)
desoxycorticosterone pivalate (usp)
D03699
21-(2,2-dimethyl-1-oxopropoxy)pregn-4-ene-3,20-dione
brn 3174879
einecs 212-366-0
corticosterone, deoxy-, pivalate (6ci,7ci)
nsc 95278
pregn-4-ene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-
3,20-dioxopregn-4-en-21-yl 2,2-dimethylpropanoate
CHEBI:50782 ,
NCGC00160511-01
DB01134
11-deoxycorticosterone pivalate
desoxycortone pivalate
deoxycortone pivalate
docp
CHEMBL1200592
A839987
[2-[(8s,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl] 2,2-dimethylpropanoate
dtxcid6026036
cas-808-48-0
tox21_111599
dtxsid8046036 ,
desoxycorticosterone pivalate [orange book]
desoxycorticosterone trimethyl acetate
desoxycorticosterone pivalate [vandf]
desoxycorticosterone pivalate [green book]
desoxycorticosterone pivalate [usp monograph]
zycortal
desoxycortone pivalate [who-dd]
desoxycorticosterone pivalate [usp-rs]
desoxycorticosterone pivalate [mi]
desoxycortone pivalate [mart.]
desoxycortone pivalate [ema epar veterinary]
11-deoxy corticosterone pivalate
SCHEMBL120007
3,20-dioxopregn-4-en-21-yl pivalate
W-104224
desoxycorticosteronepivalate
AKOS032428733
[2-[(8s,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate
CS-0030864
HY-107917
Q27092729
desoxycorticosterone-pivalate
MS-27182
2-[(1s,3as,3bs,9ar,9bs,11as)-9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl 2,2-dimethylpropanoate
EN300-1068306
Z2379810073
desoxycorticosterone pivalate (usp-rs)
desoxycortone pivalate (mart.)
desoxycortone pivalate (ema epar veterinary)
percorten-v
desoxycorticosterone pivalatae
zycortal suspension
desoxycorticosterone pivalate (usp monograph)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"Clinicians alter dosing for desoxycorticosterone pivalate (DOCP) to mitigate costs, but this practice has not been critically evaluated in a prospective clinical trial."( Desoxycorticosterone Pivalate Duration of Action and Individualized Dosing Intervals in Dogs with Primary Hypoadrenocorticism.
Cannon, AB; DeClue, AE; Jaffey, JA; Nurre, P, 2017
)
0.46
" Overall, the final DOCP dosing interval for all dogs that completed phase II (n = 36) ranged from 38 days to 90 days (median, 58 days; CI, 53, 61)."( Desoxycorticosterone Pivalate Duration of Action and Individualized Dosing Intervals in Dogs with Primary Hypoadrenocorticism.
Cannon, AB; DeClue, AE; Jaffey, JA; Nurre, P, 2017
)
0.46
" The DOCP dosage was adjusted to obtain an injection interval of 28-30 days and to keep serum electrolyte concentrations within the reference interval."( Evaluation of a low-dose desoxycorticosterone pivalate treatment protocol for long-term management of dogs with primary hypoadrenocorticism.
Boretti, FS; Hofer-Inteeworn, N; Hofmann-Lehmann, R; Kuemmerle-Fraune, C; Müller, C; Reusch, CE; Sieber-Ruckstuhl, NS, 2019
)
0.51
"Desoxycorticosterone pivalate (DOCP) is a commonly used mineralocorticoid replacement for dogs with primary hypoadrenocorticism (HA), but manufacturer-recommended dosing protocols can be cost-prohibitive."( Low-dose desoxycorticosterone pivalate treatment of hypoadrenocorticism in dogs: A randomized controlled clinical trial.
Berghoff, N; Brudvig, JM; Langlois, DK; Okonkowski, LK; Olivier, NB; Refsal, KR; Vincent, AM, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
pivalate esterA carboxylic ester of pivalic acid.
mineralocorticoidMineralocorticoids are a class of steroid hormones that regulate water and electrolyte metabolism.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency1.73450.000221.22318,912.5098AID743036; AID743040; AID743053; AID743054
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency4.50880.000214.376460.0339AID720691; AID720692
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency25.11890.01789.637444.6684AID588834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (35.00)18.7374
1990's7 (17.50)18.2507
2000's0 (0.00)29.6817
2010's14 (35.00)24.3611
2020's5 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.43 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (6.82%)5.53%
Reviews0 (0.00%)6.00%
Case Studies6 (13.64%)4.05%
Observational0 (0.00%)0.25%
Other35 (79.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]